Introduction {#s1}
============

International guidelines recommend that for patients who present with symptoms suggestive of an acute coronary syndrome (ACS), attending emergency medical service (EMS) personnel record a 12-lead ECG before transit to hospital.[@R1] This prehospital ECG (PHECG) may allow targeted treatments to be given outside of a hospital, determine which type of hospital receives the patient, and facilitate activation of the cardiac catheter laboratory.

Failure to perform a PHECG is associated with delayed and denied reperfusion treatment in patients with ST-elevation myocardial infarction (STEMI).[@R5] Although some reports suggest that women are less likely than men to have a PHECG recorded,[@R10] there is incomplete understanding of the factors associated with the use of PHECG and its impact on processes of care and mortality.

Furthermore, despite calls for widespread implementation, there is little empirical evidence that PHECG is associated with lower mortality.[@R3] [@R4] That is, much of the previous literature focuses on processes of care such as the time to reperfusion with fibrinolytic drugs, or primary percutaneous coronary intervention (PPCI).[@R5]

In England and Wales, EMS involvement in the care of patients with STEMI is the highest in Europe,[@R11] and ECGs have been available through the National Health Service (NHS) EMS since 2001. This, along with the availability of national data from the Myocardial Ischaemia National Audit Project (MINAP) concerning patients hospitalised with ACS, provides a unique opportunity to study the use of PHECG in patients with STEMI and non-STEMI and its association with processes of care and mortality.[@R12]

The a priori hypotheses for this study were that STEMI and non-STEMI patients who did not receive PHECG differed in baseline clinical characteristics from those who did, and that the use of PHECG by EMS systems was associated with better processes of care and lower mortality rates.

Methods {#s2}
=======

This study was based on national ACS data from MINAP, participation in which is mandated for all hospitals in England and Wales.[@R12] Data were collected prospectively at each hospital by a secure electronic system, developed by the Central Cardiac Audit Database (CCAD), electronically encrypted and transferred online to a central database. MINAP is overseen by a multiprofessional steering group representing the stakeholders within the National Institute for Cardiovascular Outcomes Research (NICOR).[@R13] As such, this study includes data collected on behalf of the British Cardiovascular Society under the auspices of NICOR in which patient identity was protected.

The study population was drawn from 424 866 consecutive patients admitted to hospital with ACS from 228 hospitals. Patients were eligible for study if they were hospitalised between 1 January 2005 and 31 December 2009, and aged at least 18 years. For patients with multiple admissions, we used the earliest record.

We studied patients by initial diagnosis of STEMI and non-STEMI, determined by EMS personnel or the hospital clinician responsible for providing definitive treatment. Eligibility for emergency reperfusion therapy was based upon standard practice with a recommendation that patients should have a symptom duration of 12 h or less and ST segment elevation of 0.1 mV or greater in at least two contiguous leads, or 0.2 mV or greater in in V1-V3, or presumed new onset left bundle branch block.

PHECG use was defined as the recording of an ECG by EMS personnel. The date and time of call for help was registered by the EMS and the data transferred into the MINAP database by hospital staff. The date and time of reperfusion (defined as the time of first balloon inflation for PPCI and time of injection for fibrinolytics) were recorded in MINAP by hospital staff.

Each MINAP entry provides details of the patient\'s management across 122 fields,[@R14] and date of all-cause mortality from linkage to the Medical Research Information System, part of the NHS Information Centre using a unique NHS number. Data entry is subject to routine online error checking. There is a mandatory annual data validation exercise for each hospital.

Statistical analyses {#s2a}
--------------------

We used the procedure MEANS of SAS (Statistical Analysis System; SAS, Cary, North Carolina, USA) to obtain percentages, medians and interquartile ranges. ORs, with 95% CIs are presented, being more informative than p values, because the p values resulting from logistic regression with such a large dataset were, without exception, highly significant. SAS (SAS Institute) PROC LOGISTIC was used to obtain the estimates, with the dichotomous dependent variable, for example, PHECG-recorded versus PHECG-unrecorded regressed on the explanatory variables together with standardisation for case-mix using variables including those compatible with the mini-GRACE (Global Registry of Acute Coronary Events) risk score.[@R15] The covariates chosen are listed under the relevant tables. We used multiple imputation to mitigate bias due to missing data (details in online supplement).

To investigate the extent to which the provision (or not) of reperfusion in STEMI could be predicted by PHECG use, logistic regression was performed. The dependent variable was reperfusion therapy, the independent variables being PHECG, congestive heart failure (CHF), whether or not older than 75 years, previous MI, previous coronary artery bypass grafting (CABG), sex, diabetes mellitus, patient delay in hours, and calendar year of STEMI.[@R16] Missing values were accommodated as outlined above.

Mortality within 30 days (yes/no) was the dependent variable in a logistic regression (using SAS PROC LOGISTIC) with independent variables: whether or not on aspirin, age in years at admission, Body Mass Index, whether elevated marker set (yes/no), whether chronic renal failure (CRF) (yes/no), whether diabetic (yes/no), whether prior stroke (yes/no), and whether prior CHF (yes/no). An output of this logistic regression exercise, based on the model parameter estimates and the values for each patient of the independent variables for that patient, was a predicted probability of 30-day mortality for that patient. Patients were sorted in descending order by these predicted probabilities, and the resultant dataset divided into terciles (3 equinumerous, non-overlapping, exhaustive subsets). The intermediate versus lowest 30-day mortality risk was the ratio for each subclassification (eg, PHECG, no PHECG), of the corresponding numbers of patients in the middle tercile and in the lowest tercile. For the highest versus lowest 30-day mortality risk, the corresponding terciles were the highest and the lowest.

Results {#s3}
=======

Among 424 866 patients in the MINAP registry for the years of the study, 288 990(68%) were recorded as using EMS, 22 965(5.4%) were documented as not using EMS, and the method of hospital arrival was unknown for 112 911 (26.6%) ([figure 1](#HEARTJNL2013304599F1){ref-type="fig"}). [Table 1](#HEARTJNL2013304599TB1){ref-type="table"} compares baseline characteristics of patients by EMS use. After adjustment, patients who used EMS were older, more likely to be female, Caucasian, and to have had prior MI, angina, CHF, or chronic pulmonary disease (COPD) than those who did not use EMS.

###### 

Baseline characteristics: EMS versus no EMS transportation to hospital

                       Overall (n=311 955)   EMS (n=288 990)   No EMS (n=22 965)   OR estimate   95% CI
  -------------------- --------------------- ----------------- ------------------- ------------- --------------
  Basic demographics                                                                             
   Age (years) \*      72 (60, 81)           72 (61, 81)       66 (55, 77)                       
   Female              35.7%                 36.1%             30.7%               1.07          1.04 to 1.09
   Caucasian           94.7%                 95.0%             92.6%               1.44          1.36 to 1.52
   Asian               4.4%                  4.2%              6.1%                0.72          0.68 to 0.76
   Other race          0.8%                  0.8%              1.3%                0.63          0.56 to 0.72
  Risk factors                                                                                   
   Hypertension        49.9%                 49.9%             50.3%               1.00          0.97 to 1.03
   Diabetes Mellitus   19.8%                 19.8%             19.5%               1.10          1.06 to 1.14
   PAD                 4.9%                  4.9%              4.8%                0.97          0.91 to 1.03
   Current smoker      27.3%                 27.2%             29.2%               1.09          1.06 to 1.14
   Dyslipidemia        34.5%                 34.2%             37.4%               0.96          0.93 to 1.00
  Prior history                                                                                  
   Prior MI            28.5%                 28.9%             23.0%               1.33          1.27 to 1.38
   Prior PCI           9.8%                  9.7%              11.5%               0.99          0.95 to 1.03
   Prior CABG          6.7%                  6.7%              6.8%                1.06          1.00 to 1.13
   Prior CHF           6.8%                  7.0%              4.7%                1.35          1.27 to 1.44
   Prior stroke        9.2%                  9.3%              7.2%                1.30          1.22 to 1.39
   CRF                 5.1%                  5.0%              5.7%                0.84          0.80 to 0.89
   Prior angina        34.2%                 34.8%             26.6%               1.32          1.26 to 1.38
   COPD                15.8%                 16.0%             13.5%               1.24          1.19 to 1.29

Data expressed as percentages unless indicated.

\*Age in median (IQR) years.

CABG, coronary artery bypass graft; CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; EMS, emergency medical services; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention.

![Study flow chart based on initial diagnosis.](heartjnl-2013-304599f01){#HEARTJNL2013304599F1}

Of those known to have used EMS, 145 247 (50.3%) received PHECG. Between 2005 and 2009, PHECG use increased overall (51% vs 64%, adjusted OR (aOR) 2.17, 95% CI 2.12 to 2.22) and in STEMI (64% vs 79%, aOR 2.34, 95% CI 2.25 to 2.44). Compared with patients who did not receive a PHECG, those who did were younger (71 years vs 74 years, p\<0.0001), less frequently female (33.1% vs 40.3%, OR 0.87, 95% CI 0.86 to 0.89) and had fewer comorbidities. Patients who did not receive PHECG were more frequently hypertensive, had a history of stroke, CHF, CRF, angina, diabetes or (COPD) ([table 2](#HEARTJNL2013304599TB2){ref-type="table"}). Use of PHECG increased (including among women, older people, patients with CHF and those with comorbidities) over the study period ([table 4](#HEARTJNL2013304599TB4){ref-type="table"}). Patients who received PHECG had a lower baseline mortality risk measured by mini-GRACE than those who did not.[@R15]

###### 

Baseline characteristics by PHECG use in patients who came via EMS

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                              Overall\               PHECG\                 No PHECG\              OR estimate   95% CI
                                                              (n=237 074)            (n=145 247)            (n=91 827)                           
  ----------------------------------------------------------- ---------------------- ---------------------- ---------------------- ------------- --------------
  Age\*                                                       72.0 (60.6, 81.2)      70.7 (59.6, 80.1)      73.9 (62.3, 82.6)                     

  Female                                                      35.9%                  33.1%                  40.3%                  0.87          0.86 to 0.89

  White                                                       95.1%                  95.1%                  95.1%                  1.18          1.15 to 1.22

  Asian                                                       4.2%                   4.2%                   4.1%                   0.88          0.85 to 0.91

  Other race                                                  0.8%                   0.7%                   0.9%                   0.72          0.65 to 0.80

  Hypertension                                                49.9%                  48.8%                  51.6%                  0.95          0.94 to 0.97

  Diabetes mellitus                                           19.7%                  18.6%                  21.4%                  0.91          0.90 to 0.93

  PAD                                                         4.8%                   4.4%                   5.4%                   0.87          0.83 to 0.90

  Current smoker                                              27.3%                  29.1%                  24.3%                  1.21          1.19 to 1.24

  Dyslipidemia                                                34.2%                  33.9%                  34.6%                  0.95          0.93 to 0.96

  Prior MI                                                    28.5%                  28.2%                  29.0%                  1.06          1.04 to 1.08

  Prior PCI                                                   9.8%                   10.2%                  9.2%                   1.04          1.02 to 1.07

  Prior CABG                                                  6.6%                   6.6%                   6.6%                   0.98          0.96 to 1.01

  Prior CHF                                                   6.8%                   5.7%                   8.5%                   0.79          0.77 to 0.81

  Prior stroke                                                9.3%                   8.4%                   10.7%                  0.88          0.86 to 0.91

  CRF                                                         5.1%                   4.4%                   6.2%                   0.75          0.72 to 0.77

  Prior angina                                                34.3%                  33.2%                  36.1%                  0.97          0.95 to 0.98

  COPD                                                        15.9%                  14.5%                  18.0%                  0.87          0.86 to 0.89

  SBP (mm Hg, median, IQR)                                    137.0 (118.0, 156.0)   137.0 (118.0, 156.0)   137.0 (118.0, 157.0)                  

  Heart rate (beats/min, median, IQR)                         78.0 (65.0, 94.0)      77.0 (64.0, 91.0)      80.0 (67.0, 97.0)                     

  Intermediate vs lowest 30 day mortality risk (mini-GRACE)   50.0%                  48.3%                  52.9%                  1.11          1.06 to 1.17

  Highest vs lowest 30 day mortality risk (mini-GRACE)        50.0%                  46.9%                  55.0%                  0.94          0.89 to 0.99
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Age in median (IQR) years.

CABG, coronary artery bypass graft; CHF, chronic heart failure; CRF, chronic renal failure; GRACE, Global Registry of Acute Coronary Events; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; PHECG, prehospital ECG; SBP, systolic blood pressure.

The recording of PHECG was associated with longer prehospital EMS time intervals. Considering all ACS, the median time from EMS call to arrival at hospital was 6 min longer in patients who had PHECG (52 min (IQR 40.0, 66.0) versus 46 min (IQR 35.0, 62.0). Similarly, time from EMS arrival at scene to hospital arrival was 5 min longer (40 (IQR 31.0, 53.0) vs 35 (26.0, 46.0) min). The same pattern was seen for STEMI (EMS call to hospital arrival 52 (40.0, 666.0) vs 45 (33.0, 62.0) min; time in EMS care 41 (IQR 31.0, 54.0) vs 34 (25.0, 46.0) min).

The use of any reperfusion strategy (PCI or fibrinolytic) in STEMI patients was more frequent in those who had PHECG (85.3% vs 74.4%, P\<0.001), after adjustment for confounding factors. Performance of PHECG was predictive of reperfusion therapy in STEMI compared with other patient characteristics (aOR 1.70, 95% CI 1.63 to 1.78) ([figure 2](#HEARTJNL2013304599F2){ref-type="fig"}).

![Characteristics associated with use of reperfusion therapy in patients with acute ST-elevation myocardial infarction (STEMI): influence of prehospital 12-lead ECG.](heartjnl-2013-304599f02){#HEARTJNL2013304599F2}

Door-to-balloon time for patients who received PPCI for STEMI was not influenced by PHECG use (median (IQR): 46.0 (30.0, 71.0) vs 45.0 (28.0, 75.0) min, respectively). However, a significant increase in the proportion of patients who received PPCI within 90 min of calling the EMS was observed when a PHECG was recorded (27.9% vs 21.4%, aOR 1.38, 95% CI 1.24 to 1.54).

For STEMI patients receiving fibrinolytics in hospital, PHECG use was associated with a higher proportion of patients who received treatment within 30 min of arrival (90.6% vs 83.7%; aOR 2.13, 95% CI 1.91 to 2.38). The median door-to-needle interval was 3 min shorter (17 (IQR 12.0, 23.0) versus 20 (14.0, 27.0) min). However, the overall call-to-needle interval was similar between the two groups (59 (IQR 49.0, 72.0) versus 58 (47.0, 73.0 min).

Of 11 172 STEMI patients who received prehospital fibrinolytic therapy, PHECG was recorded by EMS personnel in 10 816, (96.8%). In the remainder, PHECG was performed by non-EMS personnel (eg, primary care physicians) prior to EMS arrival.

As PHECG was associated with an increased likelihood of a STEMI patient receiving any reperfusion therapy ([figure 2](#HEARTJNL2013304599F2){ref-type="fig"}), we sought to determine whether patients who did not have PHECG shared similar characteristics to those who subsequently failed to receive reperfusion treatment for STEMI. The separate baseline characteristics for these two categories were summarised and were clearly different (data on file). On account of the large numbers of patients in each category, and the overlap of patients in the two categories, any statistical judgement on the significances of these differences would be uninformative: the only meaningful comparisons would be ones based on clinical judgement.

Patients who received a PHECG exhibited significantly lower hospital and 30-day mortality rates than those who did not (30-day mortality 7.4% vs 8.2%, aOR 0.94, 95% CI 0.91 to 0.96). Most of the differences were attributable to significantly lower rates of mortality in STEMI patients who received a PHECG (8.6% vs 11.4%, aOR 0.94, CI 0.90 to 0.98). There was no difference in mortality by PHECG in STEMI patients who did not undergo any reperfusion strategy (18.6% vs 18.8%, aOR 0.96 95% CI 0.90 to 1.03). Patients with non-STEMI who received a PHECG had lower mortality than those who did not (5.9% vs 6.5%, aOR 0.84, 95% CI 0.81 to 0.88). ([table 3](#HEARTJNL2013304599TB3){ref-type="table"}).

###### 

Hospital and 30-day mortality by PHECG use

  Mortality                                              Overall       PHECG         No PHECG     Adjusted OR   95% CI
  ------------------------------------------------------ ------------- ------------- ------------ ------------- --------------
  Total population                                       (n=154 546)   (n=102 831)   (n=51 715)                  
   Hospital                                              4.2%          4.0%          4.7%         0.85          0.82 to 0.88
   30 day                                                7.6%          7.4%          8.2%         0.94          0.91 to 0.96
  STEMI patients                                         (n=72 638)    (n=54 953)    (n=17 685)                  
   Hospital                                              5.2%          4.8%          6.6%         0.88          0.84 to 0.93
   30 day                                                9.3%          8.6%          11.4%        0.94          0.90 to 0.98
  STEMI patients receiving reperfusion therapy\*         (n=62 412)    (n=48 533)    (n=13 879)                  
   Hospital                                              4.3%          4.0%          5.4%         0.92          0.85 to 0.99
   30 day                                                7.8%          7.3%          9.4%         0.94          0.89 to 1.00
  STEMI patients receiving fibrinolytic agents           (n=42 604)    (n=33 394)    (n=9210)                    
   Hospital                                              5.0%          4.6%          6.4%         0.91          0.84 to 1.00
   30 day                                                8.9%          8.3%          10.9%        0.95          0.88 to 1.01
  STEMI patients receiving pPCI                          (n=14 063)    (n=11 015)    (n=3048)                    
   Hospital                                              3.1%          2.9%          3.6%         0.89          0.72 to 1.12
   30 day                                                5.2%          5.0%          6.0%         0.91          0.77 to 1.07
  STEMI patients not receiving any reperfusion therapy   (n=10 226)    (n=6420)      (n=3806)                    
   Hospital                                              10.6%         10.5%         11.0%        0.86          0.80 to 0.93
   30 day                                                18.7%         18.6%         18.8%        0.96          0.90 to 1.03
  nSTEMI patients                                        (n=81 908)    (n=47 878)    (n=34 030)                  
   Hospital                                              3.3%          3.1%          3.7%         0.76          0.72 to 0.80
   30 day                                                6.1%          5.9%          6.5%         0.84          0.81 to 0.88

EMS, emergency medical services; PHECG, prehospital ECG; pPCi, primary percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.

Discussion {#s4}
==========

This study demonstrates that, in patients presenting with symptoms of ACS, PHECG use is significantly associated with a reduction in mortality during the 30 days following hospitalisation. This mortality benefit was seen in STEMI (where there was an association between PHECG and an increased likelihood of, and reduced delay to, reperfusion) and in non-STEMI. PHECG use increased over the study period (including among women, older people, CHF patients and those with comorbidities), but was still suboptimal at approximately two-thirds of eligible patients with ACS (almost 80% in STEMI). Patients with higher mortality risk at baseline, as assessed using the mini-GRACE score, were less likely to receive PHECG.

Although prehospital time was increased for those who had received PHECG, in-hospital processes of care were improved, particularly for STEMI. Moreover, the risk of death was lower in STEMI and non-STEMI even after adjustment for confounding effects. In-hospital and 30-day mortality rates in those receiving PHECG and PPCI for STEMI were 11% and 4% lower, respectively---suggesting a similar beneficial effect as in most other groups of patients, but in this case failing to reach statistical significance at the 95% level.

Our study population differs from previously published series in several ways. First, our patients were older; 72 (60, 81) years compared with 61 years in the NRMI-4 Registry,[@R5] and 62 (52,75) years in the NCD-ACTION Registry,[@R8] and 62 years in the series reported by Patel *et al.*[@R17] The proportion of EMS patients who were female was similar to NCD-ACTION[@R8] (36.1% vs 34.1%) but lower than the 47% reported by Patel *et al*.[@R17]

Previous reports suggest sex differences in prehospital management of ACS. Rothcock *et al* reported that PHECG use was significantly lower in women than men (32.9% vs 39.3%, p\<0.001).[@R18] Our study suggests that patients who did not have PHECG were more frequently older, female and comorbid.

It is possible that, in a predominantly male EMS workforce, staff were reluctant to undertake PHECG in female patients because of the need for intimate exposure. This phenomenon has been reported elsewhere.[@R18] [@R19] Meisel *et al*[@R20] found that including EMS provider sex in their logistic regression model did not change differences observed between patient sex and rates of prehospital use of ACS protocol interventions (although PHECG was not included in the EMS protocols). We did not collect data on patient preferences, and it is possible that women were less likely than men to consent to having a PHECG recorded.

We have shown that, in contrast to other patient variables, having a PHECG recorded is associated with the provision of reperfusion therapy for STEMI. In an analysis of the GRACE,[@R16] PHECG was not included in the model to assess characteristics associated with failure to use reperfusion therapy.

The role of the PHECG in patients with non-STEMI ACS has received little attention in previous studies. Cudnick *et al*[@R10] reported that of 21 151 patients with non-STEMI in the NCDR-ACTION-get with the guidelines (GWTG) registry, a PHECG was documented in only 1609 (7.6%), and the primary outcomes of interest were process measures including use of aspirin, β-blocker and heparin and length of stay in the Emergency Department (ED). Since MINAP does not collect these data, we were unable to compare our findings. Cudnick *et al* did not find an association between PHECG and lower mortality for non-STEMI. The precise mechanism whereby the recording of a PHECG was associated with lower mortality in our series remains unexplained and requires further evaluation.

Our study should be interpreted in the context of the following limitations. Given the observational nature of our research, we are not able to establish causality.[@R21] Our analysis was dependent upon the extent and validity of data in the MINAP database. We used multiple imputation to mitigate bias due to missing data.[@R22] It is possible, however, that those with missing data were the most seriously ill, and it was more difficult to obtain and record accurate data for the MINAP database (eg, those who died prior to hospital arrival or in the ED), and we cannot exclude this potential source of bias.

MINAP does not collect data on presenting symptoms, and we were therefore unable to ascertain clinical indications for recording a PHECG. Nor were we able to distinguish between cases where the PHECG was transmitted electronically for expert review (eg, by a cardiologist[@R23] or cardiac care unit (CCU) nurse[@R24]) or interpreted by EMS staff. Ducas *et al*[@R25] report that non-physician EMS interpretation of PHECG is safe and reliable. We were also unable to ascertain the skill level of EMS staff: in England and Wales, ambulances are staffed by a combination of paramedics (trained in advanced life support and ECG interpretation) and emergency medical technicians trained in basic life support and use of an automated external defibrillator, but not in ECG interpretation. It is possible that paramedics underwent a different process of clinical assessment and decision making, and this may have implications for appropriateness of cardiac catheter laboratory activation.[@R26] It is possible that increased availability of PPCI following publication of national guidance in 2008 could result in an increase in PHECG use, but we did not identify an increase in PHECG use from 2008 to 2009 ([table 4](#HEARTJNL2013304599TB4){ref-type="table"}).[@R27]

###### 

Changes in use of PHECG in patients who used EMS, by year

  PHECG use---no./total no. (%)                                                                                     
  ------------------------------- -------------------- --------------------- --------------------- ---------------- --------------------
  2005                            16 465/32 410 (51)   5515/11 874 (46)      6259/13 464 (46)      953/2332 (41)    12 425/25 053 (50)
  2006                            26 545/44 568 (60)   8848/16 031 (55)      10 233/18 581 (55)    1465/2874 (51)   19 915/34 048 (58)
  2007                            30 303/47 806 (63)   9915/16 968 (58)      11 826/20 264 (58)    1669/3003 (56)   22 740/36 627 (62)
  2008                            33 431/51 812 (65)    10 935/18 411 (59)   12 787/21 554 (59)    1831/3388 (54)   25 317/39 976 (63)
  2009                            38 503/60 478 (64)   12 690/21 545 (59)     15 084/25 265 (60)   1970/3653 (54)   28 907/46 402 (62)

CHF, chronic heart failure; EMS, emergency medical services; PHECG, prehospital ECG.

Conclusions {#s5}
===========

Findings from this national MI registry demonstrate for the first time a survival advantage in STEMI and non-STEMI patients when PHECG was used. This study strengthens the evidence base for guidelines which recommend PHECG. However, use was variable, indicating the need for quality improvement interventions. Such interventions need to be evaluated through randomised trials in order to provide rigorous evidence of their clinical and cost effectiveness. Key messages**What is already known on this subject?**Use of the PHECG has been recommended in international guidelines for ST-elevation myocardial infarction (STEMI), but while several reports of the impact of processes, such as reperfusion times have been published, there have been no data exploring the association of PHECG with patient outcome, and little is known about the impact of PHECG on patients with non-STEMI ACS.**What this study adds**Findings from this national MI registry demonstrate for the first time a survival advantage associated with PHECG use, in patients with STEMI and non-STEMI. It also identifies categories of patients in whom PHECG is underutilised.**How might this impact on clinical practice?**This study strengthens the evidence base for existing guidelines, and identifies the need for interventions to increase PHECG use in categories of patients in which it is currently underutilised.
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